Media Digest (1/9/2012) Reuters, WSJ, NYT, FT, Bloomberg

http://platform.twitter.com/widgets/hub.1324331373.htmlThe U.S. may start legal proceedings against Swiss financial firm Wegelin & Co. based on beliefs that it helped shield Americans from taxes. (Reuters)

The EPA may send fresh water to communities close to fracking sites. (Reuters)

The International Monetary Fund says that Europe may avoid a 2012 recession, but that some areas are in deep trouble. (Reuters)

China may create a large ministry to oversee the nation’s energy. (Reuters)

Merkel and Sarkozy will meet to discuss ways to stimulate job growth in Europe. (Reuters)

The euro reaches a 16-month low against the dollar. (Reuters)

Olympus is close to a delisting from the Tokyo stock exchange. (Reuters)

Lions Gate (NYSE: LGF) is about to buy Summit, which created the Twilight series. (Reuters)

Pay cuts on Wall St. will be large for 2012. (WSJ)

Detroit car companies have begun to introduce new models to fight back against Japanese and European brands. (WSJ)

Unemployment problems are likely to last many years in the U.S. (WSJ)

Occupancy rates at malls saw a small improvement late last year. (WSJ)

BMW claims it will outperform the car market next year. (WSJ)

Weight Watchers (NYSE: WTW) will begin to market to men and to the Chinese. (WSJ)

General Motors (NYSE: GM) says Volt production will meet demand, but did not say what the demand is. (WSJ)

Time Warner’s (NYSE: TWX) Warner Bros. will delay DVD releases for eight weeks after theater release, up from four weeks. (WSJ)

The Canadian government to begin deliberations on a pipeline to run from its oil sands areas to the Pacific ocean. (WSJ)

Venezuela may stop working with the World Bank’s tribunal, which would leave billions of dollars in disputes in limbo. (WSJ)

Microsoft (NASDAQ: MSFT) says it will rely on Intel (NASDAQ: INTC) less for product platforms, but that may be challenged by the software firm’s problems in mobile devices. (WSJ)

Bristol-Myers (NYSE: BMY) to buy hepatitis C drug-developer Inhibitex (NASDAQ: INHX) for $2.5 billion. (WSJ)

RHR International, a research firm, says more CEOs feel under pressure to deliver short-term results. (WSJ)

A European Central Bank meeting likely will not yield any aid for nations in the region that are part of the financial crisis. (WSJ)

A slowdown of trading will hurt Wall St. Q4 results. (WSJ)

Ford (NYSE: F) will gamble on its mid-sized Fusion to beat Japanese competition. (NYT)

Germany is unlikely to offer more money for bailouts as its belief in effective austerity grows. (NYT)

The oversight panel of the Basel Committee on Banking Supervision says some banks may be able to drop below capital requirements. (NYT)

The UK may still give the IMF a large sum, intended mostly for a bailout of some eurozone nations. (FT)

S&P 500 earnings growth likely will stumble. (FT)

The ECB could cut interest rates much as the Federal Reserve did. (Bloomberg)

A strong export economy helps keep Germany out of recession. (Bloomberg)

Douglas A. McIntyre